Symptom Clusters in Children With Leukemia

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Duke University Identifier:
First received: October 15, 2012
Last updated: October 1, 2015
Last verified: October 2015

The purpose of this study is to examine the phenotypic and genotypic characteristics and their associations with symptom clusters experienced during treatment for childhood leukemia.

Childhood Leukemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Phenotypic and Genotypic Associations With Symptom Clusters During Childhood Leukemia Treatment

Resource links provided by NLM:

Further study details as provided by Duke University:

Biospecimen Retention:   Samples With DNA

A baseline CSF sample will be obtained prior to intrathecal chemotherapy. CSF biomarkers will be obtained at the initiation of post-induction, 4 and 6 months into post-induction therapy, and at the start of maintenance therapy.A saliva sample will be obtained for genotypic analysis at one of the four data collection times.

Estimated Enrollment: 400
Study Start Date: November 2012
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Detailed Description:

A repeated measures research design will evaluate phenotypic and genotypic treatment-related symptom associations experienced by children and adolescents 3-17 years of age with a diagnosis of leukemia.


Ages Eligible for Study:   3 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Children between 3-18 years of age undergoing treatment for leukemia.


Inclusion Criteria:

  • Phenotypic and genotypic treatment-related symptom associations will be evaluated in children and adolescents 3-18 years of age with a diagnosis of leukemia.

Exclusion Criteria:

  • Children without a definite diagnosis of leukemia will be excluded.
  • Children must be able to understand and answer the questions on the questionnaires.
  • Children with have a cognitive impairment (e.g. Down syndrome) will not be able to complete the questionnaires and will not be eligible for the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01708421

United States, Arizona
University of Arizona
Tucson, Arizona, United States, 85721-0203
United States, Minnesota
Children's Hospitals & Clinics of Minnesota
Minneapolis, Minnesota, United States, 55404
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599-7460
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Texas
Baylor College of Medicine/ Texas Children's Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Duke University
Principal Investigator: Marilyn Hockenberyy, PhD Duke University School of Nursing
  More Information

No publications provided

Responsible Party: Duke University Identifier: NCT01708421     History of Changes
Other Study ID Numbers: Pro00037891
Study First Received: October 15, 2012
Last Updated: October 1, 2015
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Pathologic Processes processed this record on October 02, 2015